AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7714088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (fed and fasted)
Number of subjects: 12
Study 2785610 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based educational program with parental involvement and mass media coverage
Number of subjects: 22500
Study 2785610 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control condition
Number of subjects: 22500
Study 825745 — intervention group
Group type: EXPERIMENTAL
Intervention: Trental 400 (1 tablet 3 times a day for 7 to 8 weeks)
Number of subjects: 40
Study 825745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6446269 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein
Number of subjects: 87
Study 6446269 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE)
Number of subjects: 87
Study 6446269 — intervention group
Group type: COMPARATOR
Intervention: Composite Dacron-autogenous vein (DV) grafts
Number of subjects: 87
Study 30679671 — intervention group
Group type: EXPERIMENTAL
Intervention: Active formula (NUTURIS, large phospholipid coating of lipid droplets, mode diameter 3‐5 μm)
Number of subjects: 29
Study 30679671 — intervention group
Group type: COMPARATOR
Intervention: Control formula (commercially available formula with smaller lipid droplets)
Number of subjects: 29
Study 27798454 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube suction II (LTS II)
Number of subjects: 50
Study 27798454 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 50
Study 24831862 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 74
Study 24831862 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 74
Study 24237617 — intervention group
Group type: EXPERIMENTAL
Intervention: myCompass program
Number of subjects: 720
Study 24237617 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention
Number of subjects: 720
Study 24237617 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 720
Study 21464755 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-free infant rice cereal
Number of subjects: 39
Study 21464755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pureed carrots
Number of subjects: 39
Study 19526329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics counseling
Number of subjects: 36
Study 19526329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics counseling + Myofeedback training
Number of subjects: 36
Study 19526329 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ergonomics counseling only)
Number of subjects: 36
Study 17198065 — intervention group
Group type: EXPERIMENTAL
Intervention: Conveen anal plug (Coloplast Limited) used for 12 months
Number of subjects: 48
Study 17198065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anal plug)
Number of subjects: 48
Study 15132131 — intervention group
Group type: COMPARATOR
Intervention: 4 x 100‐mg capsules (reference)
Number of subjects: 33
Study 15132131 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 100‐mg tablets (test)
Number of subjects: 33
Study 15132131 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 400‐mg tablet (test)
Number of subjects: 33
Study 15132131 — intervention group
Group type: COMPARATOR
Intervention: 4 x 100‐mg tablets versus 4 x 100‐mg capsules
Number of subjects: 33
Study 15132131 — intervention group
Group type: COMPARATOR
Intervention: 1 x 400‐mg tablet versus 4 x 100‐mg capsules
Number of subjects: 33
Study 15132131 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 33
Study 12034517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol sequentially combined with dydrogesterone (oE2/D10)
Number of subjects: 119
Study 12034517 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol plus norethisterone acetate (tdE/NETA)
Number of subjects: 119
Study 10464826 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacehaler (250 micrograms beclomethasone dipropionate)
Number of subjects: 12
Study 10464826 — intervention group
Group type: COMPARATOR
Intervention: MDI (250 micrograms beclomethasone dipropionate)
Number of subjects: 12
Study 10464826 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacehaler
Number of subjects: 12
Study 10464826 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 12
Study 7853047 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment for acute myocardial infarction
Number of subjects: 0
Study 7853047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 7853047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of death from bleeding peptic ulcers
Number of subjects: 0
Study 2404436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine, adrenaline, and cocaine (TAC)
Number of subjects: 139
Study 2404436 — intervention group
Group type: COMPARATOR
Intervention: Cocaine alone
Number of subjects: 139
Study 402508 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 day regimen of cephalothin prophylaxis
Number of subjects: 200
Study 402508 — intervention group
Group type: COMPARATOR
Intervention: 2 day regimen of cephalothin prophylaxis
Number of subjects: 200
Study 402508 — intervention group
Group type: EXPERIMENTAL
Intervention: No detectable cephalothin in sera
Number of subjects: 200
Study 402508 — intervention group
Group type: COMPARATOR
Intervention: Detectable cephalothin in sera
Number of subjects: 200
Study 31586420 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 86
Study 31586420 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 86
Study 31586420 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg no load
Number of subjects: 86
Study 31586420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30860570 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib (400 mg b.i.d. 4 days on/3 days off) with paclitaxel (90 mg/m2 on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 148
Study 30860570 — intervention group
Group type: COMPARATOR
Intervention: Placebo with paclitaxel (90 mg/m2 on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 148
Study 28814770 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stress physiology of sister cells after a semi-lethal heat challenge
Number of subjects: 0
Study 26336043 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Compression Therapy (ACT)
Number of subjects: 12
Study 26336043 — intervention group
Group type: COMPARATOR
Intervention: 4-Layer Bandage (4LB)
Number of subjects: 12
Study 23252914 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge-planning intervention combining chronic drug review, education, and enhanced transition-of-care communication
Number of subjects: 665
Study 23252914 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 665
Study 23252914 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge-planning intervention
Number of subjects: 665
Study 21602474 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% MVC
Number of subjects: 11
Study 21602474 — intervention group
Group type: COMPARATOR
Intervention: 5% MVC
Number of subjects: 11
Study 19635148 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal artery stenting (PTRAS) plus best medical treatment
Number of subjects: 0
Study 19635148 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 0
Study 19635148 — intervention group
Group type: EXPERIMENTAL
Intervention: PTRAS
Number of subjects: 0
Study 16636345 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia at 434 MHz
Number of subjects: 37
Study 16636345 — intervention group
Group type: COMPARATOR
Intervention: Continuous ultrasound at 1 MHz at an intensity of 2.0 w/cm(2) 3 times a week
Number of subjects: 37
Study 16636345 — intervention group
Group type: COMPARATOR
Intervention: Exercises (pendular swinging and stretching exercises 5 minutes twice a day every day)
Number of subjects: 37
Study 14752407 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐stat strategy
Number of subjects: 40
Study 14752407 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐stat
Number of subjects: 40
Study 12468560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg daily
Number of subjects: 439
Study 12468560 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 50 mg daily
Number of subjects: 439
Study 12468560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout group
Number of subjects: 439
Study 9438743 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug run-in period
Number of subjects: 0
Study 9438743 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported results of studies with run-in periods
Number of subjects: 0
Study 9438743 — intervention group
Group type: COMPARATOR
Intervention: Results without run-in period
Number of subjects: 0
Study 7699089 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial color-coded sonography (TCCS)
Number of subjects: 20
Study 7699089 — intervention group
Group type: COMPARATOR
Intervention: Transcranial Doppler (TCD)
Number of subjects: 20
Study 2703763 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming in chlorinated water (Group 1)
Number of subjects: 30
Study 2703763 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-swimming assessment)
Number of subjects: 30
Study 2703763 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming in chlorinated water (Group 2)
Number of subjects: 30
Study 851303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose-concentration dialysate (717 mg/dl)
Number of subjects: 0
Study 851303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mannitol (1g/kg)
Number of subjects: 0
Study 851303 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-glucose-concentration dialysate and intravenous mannitol
Number of subjects: 0
Study 851303 — intervention group
Group type: COMPARATOR
Intervention: Control (regular dialysis)
Number of subjects: 0
Study 851303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose-concentration dialysate and intravenous mannitol
Number of subjects: 0
Study 31304909 — intervention group
Group type: COMPARATOR
Intervention: 100% nitrogen application in control environment
Number of subjects: 0
Study 31304909 — intervention group
Group type: COMPARATOR
Intervention: 33% nitrogen application in manure environment
Number of subjects: 0
Study 31304909 — intervention group
Group type: COMPARATOR
Intervention: 66% nitrogen application in compost environment
Number of subjects: 0
Study 31304909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vermicompost fertilizer and Azosperillum + Azotobacter
Number of subjects: 0
Study 31304909 — intervention group
Group type: EXPERIMENTAL
Intervention: Different levels of nitrogen fertilizer
Number of subjects: 0
Study 29945920 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (0.03-6 mg, n=6 across seven cohorts)
Number of subjects: 56
Study 29945920 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (0.03-6 mg)
Number of subjects: 56
Study 29945920 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (0.3-6 mg)
Number of subjects: 56
Study 29945920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2/cohort)
Number of subjects: 56
Study 26787147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Scale-Up (RSU) program
Number of subjects: 9
Study 26787147 — intervention group
Group type: COMPARATOR
Intervention: Comparison area (no RSU program)
Number of subjects: 9
Study 25331767 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 25331767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22360996 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 times per week daily in-center hemodialysis)
Number of subjects: 332
Study 22360996 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis (6 times per week nocturnal hemodialysis)
Number of subjects: 332
Study 22360996 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 332
Study 20175405 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective SWS disruption by acoustic stimuli
Number of subjects: 110
Study 20175405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disruption)
Number of subjects: 110
Study 18063446 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal subunit influenza vaccine (vSIV, brand: Invivac)
Number of subjects: 386
Study 18063446 — intervention group
Group type: COMPARATOR
Intervention: MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad)
Number of subjects: 386
Study 18063446 — intervention group
Group type: COMPARATOR
Intervention: Conventional subunit influenza vaccine (SIV, brand: Influvac)
Number of subjects: 386
Study 18063446 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 386
Study 18063446 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal subunit influenza vaccine (vSIV)
Number of subjects: 386
Study 15606445 — intervention group
Group type: EXPERIMENTAL
Intervention: NMI 861
Number of subjects: 28
Study 15606445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11879828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary hip screw (IMHS)
Number of subjects: 102
Study 11879828 — intervention group
Group type: COMPARATOR
Intervention: Compression hip screw (CHS)
Number of subjects: 102
Study 10527227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 microg/kg)
Number of subjects: 40
Study 10527227 — intervention group
Group type: COMPARATOR
Intervention: IT placebo
Number of subjects: 40
Study 8669361 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation by means of intravenous midazolam (0.1 mg/kg)
Number of subjects: 426
Study 8669361 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia only
Number of subjects: 426
Study 2045854 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy for 12 courses
Number of subjects: 486
Study 2045854 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy for 8 courses followed by Adriamycin for 4 courses
Number of subjects: 486
Study 7319877 — intervention group
Group type: COMPARATOR
Intervention: Slow isokinetic training at 60 degrees/s
Number of subjects: 0
Study 7319877 — intervention group
Group type: COMPARATOR
Intervention: Mixed isokinetic training at 60 and 300 degrees/s
Number of subjects: 0
Study 7319877 — intervention group
Group type: COMPARATOR
Intervention: Fast isokinetic training at 300 degrees/s
Number of subjects: 0
Study 7319877 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group receiving low‐level muscle stimulation
Number of subjects: 0
Study 31035054 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong injection (DHI)
Number of subjects: 42
Study 31035054 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical constituents of DHI (danshensu; lithospermic acid, LA; salvianolic acid D, SaD)
Number of subjects: 42
Study 29263483 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged-hybrid coronary revascularization (staged-HCR)
Number of subjects: 70
Study 29263483 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive total arterial revascularization with BITA
Number of subjects: 70
Study 25733743 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy (n = 100)
Number of subjects: 200
Study 25733743 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 100)
Number of subjects: 200
Study 25158767 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaped implants
Number of subjects: 0
Study 25158767 — intervention group
Group type: COMPARATOR
Intervention: Round implants
Number of subjects: 0
Study 25158767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study 22435856 — intervention group
Group type: EXPERIMENTAL
Intervention: ScvO(2) goal achievement (≥70%)
Number of subjects: 203
Study 22435856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate clearance (LC) goal achievement (≥10% decrease)
Number of subjects: 203
Study 22435856 — intervention group
Group type: EXPERIMENTAL
Intervention: No agreement between LC and ScvO(2) goal achievement
Number of subjects: 203
Study 19187400 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 57
Study 17133582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (median dose 0.35 mg/day)
Number of subjects: 345
Study 17133582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (median dose 0.47 mg/day)
Number of subjects: 345
Study 15878754 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF gene polymorphism (BstUI C/T) in patients with oral cancer
Number of subjects: 367
Study 15878754 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (healthy individuals)
Number of subjects: 367
Study 15878754 — intervention group
Group type: EXPERIMENTAL
Intervention: T/C ratio in patients with oral cancer
Number of subjects: 367
Study 11955903 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 40
Study 11955903 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 40
Study 9592637 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise on a treadmill during hypoglycaemia
Number of subjects: 10
Study 9592637 — intervention group
Group type: COMPARATOR
Intervention: Rest during hypoglycaemia
Number of subjects: 10
Study 7618721 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 27
Study 7618721 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 27
Study 1282616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg, twice daily for 21 days)
Number of subjects: 16
Study 6369366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 2
Study 6369366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30797386 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Couple Therapy (ABCT)
Number of subjects: 188
Study 29509108 — intervention group
Group type: EXPERIMENTAL
Intervention: Photograph-based telemedicine review
Number of subjects: 37
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% decrease in colonoscopy reimbursement
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% decrease in colonoscopy reimbursement
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% decrease in colonoscopy reimbursement
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% decrease in colonoscopy reimbursement
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement plans after 2030
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% reimbursement reduction (retirement subgroup)
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% reimbursement reduction (retirement subgroup)
Number of subjects: 2009
Study 26781428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% reimbursement reduction (retirement subgroup)
Number of subjects: 2009
Study 25694481 — intervention group
Group type: EXPERIMENTAL
Intervention: High Sodium (HS) intake (7 days, 200 mmol Na(+)/24 h)
Number of subjects: 36
Study 25694481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sodium (Na) intake (7 days, 50 mmol Na(+)/24 h)
Number of subjects: 36
Study 25694481 — intervention group
Group type: EXPERIMENTAL
Intervention: ANG II infusion
Number of subjects: 36
Study 25694481 — intervention group
Group type: COMPARATOR
Intervention: Control group (fHP women)
Number of subjects: 36
Study 23496006 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft music
Number of subjects: 93
Study 23496006 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 93
Study 19940229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of golimumab 100 mg (30‐minute infusion, n = 23)
Number of subjects: 78
Study 19940229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of golimumab 100 mg at upper arm (n = 18)
Number of subjects: 78
Study 19940229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of golimumab 100 mg at abdomen (n = 18)
Number of subjects: 78
Study 19940229 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of golimumab 100 mg at thigh (n = 19)
Number of subjects: 78
Study 19940229 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SC administration of golimumab 100 mg
Number of subjects: 78
Study 19940229 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of golimumab 100 mg
Number of subjects: 78
Study 19940229 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of golimumab 100 mg
Number of subjects: 78
Study 18379535 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin solution
Number of subjects: 0
Study 18379535 — intervention group
Group type: COMPARATOR
Intervention: Glucose solutions
Number of subjects: 0
Study 16802519 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers, ACE inhibitors/AT1 receptor antagonists, diuretics, aldosterone antagonists, and glycosides (specific dosages and durations not available)
Number of subjects: 0
Study 14581346 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib once a day for 9 months
Number of subjects: 21
Study 14581346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14581346 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib once a day
Number of subjects: 21
Study 10947698 — intervention group
Group type: COMPARATOR
Intervention: Caudal ropivacaine 0.2% 1 ml/kg
Number of subjects: 32
Study 10947698 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine 0.2% 1 ml/kg plus caudal ketamine 0.25 mg/kg
Number of subjects: 32
Study 9224783 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C]avitriptan 20 mg/kg iv and oral in rats; 10 mg iv and 50 mg oral in humans
Number of subjects: 0